Core Viewpoint - The company is focusing on optimizing its product structure and maintaining a solid operational foundation while nurturing core products and those priced above 100 yuan [1][2]. Group 1: Product Strategy - The company has been promoting the cultivation of premium products, with products priced above 100 yuan showing year-on-year growth of 5.3% for the full year 2024 and 25.5% for Q1 2025 [1]. - Key products such as "甲等 15" and "1915" have demonstrated effective cultivation in the mid-to-high price segments [1]. Group 2: Financial Management - The company is implementing refined expense management, shifting its expenditure structure towards direct consumer engagement (C-end) [2]. - The strategy focuses on "precise investment" and reducing broad channel spending, enhancing consumer reach and terminal sales effectiveness [2]. - The company anticipates an upward trend in personnel costs due to the need for higher quality in the sales team and brand engagement [2]. Group 3: Brand and Market Expansion - The company is pursuing a multi-brand strategy to enhance national presence, with a focus on "core brand consolidation + regional brand breakthroughs" [2]. - The "武陵酒" brand is expected to continue its double-digit growth and accelerate national expansion through a short-chain direct sales model [2][3]. Group 4: Profit Forecast - The company projects revenues of 5.471 billion yuan and 5.917 billion yuan for 2025 and 2026, respectively, representing year-on-year growth of 2.1% and 8.2% [3]. - Expected net profits for the same years are 842 million yuan and 891 million yuan, with growth rates of 4.6% and 8.2% [3].

Group 1: Company Overview - The company has seen significant revenue growth and steady profit improvement in its GNC China business, but there is still room for optimization in expense management [1] - The company plans to actively explore the potential of commercial contract promotion and implement various measures to reduce costs and improve efficiency, focusing on precise allocation of sales expenses [1] - The company aims to strengthen brand value and promote compliant, high-quality development of its GNC China business while closely monitoring market dynamics [1] Group 2: Market and Product Development - The orthopedic external patch market in China has exceeded 10 billion, with a compound annual growth rate of 9.55% driven by aging population and chronic disease management awareness [2] - The company is focusing on the development of traditional Chinese medicine combined with modern transdermal technology for its key prescription product, the wind-dispelling pain gel [2] - The company plans to continue digital and intelligent transformation of its traditional Chinese medicine production lines to enhance efficiency and responsiveness to national policy [2] Group 3: Future Product Pipeline - The company has received approval for a generic drug, lactulose oral solution, and is progressing with two other products through consistency evaluation [2] - Upcoming products expected to be approved in the next two years include oseltamivir phosphate dry suspension and iron protein succinate oral solution, among others [2] - The company will focus on major disease areas such as cardiovascular, digestive metabolism, respiratory, anti-infection, and anti-tumor, with an emphasis on developing medications for the elderly and children [2] Group 4: Financial Management - The company disclosed that its interest income comes solely from bank deposits, with no involvement in financial products or lending for interest income [3] - The company emphasizes a scientific and reasonable financial planning approach to maintain sufficient debt repayment capacity and a reasonable capital structure [3] - The company has established a budget management system to ensure that every expense has a responsible party and approval process, with regular evaluations and adjustments [3][4]